ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/SA/5011-Woodville-South-The-Queen-Elizabeth-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
29
trial(s) found.
NCT07244705
Advanced
Phase 1 / Phase 2
Recruiting
An Open-label, Multicenter, Phase 1/2 Study Exploring the Safety and Efficacy of ABT-301 in Combination With Tislelizumab and Bevacizumab in Participants With Proficient Mismatch Repair (pMMR)/Non-Microsatellite Instability-High (Non-MSI-H) Locally Advanced or Metastatic Colorectal Cancer (mCRC) (
ABT-301-103
)
HDAC inhibitor
anti-PD-1 monoclonal antibody
anti-VEGF monoclonal antibody
Colorectal cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT07235293
Advanced
Phase 2
Recruiting
A Randomized, Open-label, Phase 2b Study to Compare the Efficacy of DSP107 in Combination With Atezolizumab Versus Fruquintinib in Patients With Advanced Microsatellite Stable Colorectal Cancer (
DSP107-003
)
VEGFR1/2/3 inhibitor
anti-PD-L1 monoclonal antibody
bifunctional CD47/4-1BB fusion protein
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3011 - Footscray - Footscray Hospital
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT07098338
Advanced
Phase 2
Recruiting
An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (
LIBRA
)
Datopotamab Deruxtecan
Ramucirumab
Rilvegostomig
anti-Trop2 antibody-drug conjugate
anti-VEGFR2 monoclonal antibody
bispecific PD-1/TIGIT antibody
cancer therapy
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,TIGIT-targeting
cancer therapy,Trop2-targeting
cancer therapy,VEGFR2-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,Trop2-targeting
immuno-oncology therapy,VEGFR2-targeting
therapeutic modality,bispecific antibody
Non-small cell lung cancer
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT07094113
Advanced
Phase 1
Recruiting
A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
pan-KRAS inhibitor
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT07086105
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Preliminary Efficacy of Intratumoural Adze1.C in Participants With Metastatic Melanoma (
ADZE1.C-001
)
oncolytic virus,CD40L-payload
Melanoma
VIC
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Tasman Oncology
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT07076121
Advanced
Phase 2 / Phase 3
Recruiting
A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion (
CA240-0030
)
PRMT5 inhibitor,MTA-co-operative
antimetabolite
placebo
taxane
Pancreatic adenocarcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
VIC
3066 - Epping - Northern Hospital
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07015190
Curative
Phase 3
Recruiting
A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-metastatic Uveal Melanoma (OptimUM-10) (
IDE196-010
)
PKC inhibitor
Uveal melanoma
VIC
3004 - Melbourne, Southbank - Alfred Health
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NA
NA
NCT07005102
Advanced
Phase 2 / Phase 3
Recruiting
A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer (
M25-287
)
EGFR inhibitor,third generation
anti-cMET antibody-drug conjugate
Non-squamous non-small-cell lung cancer
NSW
2170 - Liverpool - Liverpool Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6150 - Murdoch - St John of God Murdoch Hospital
NCT06820463
Advanced
Phase 2
Recruiting
A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer (
AndroMETa-CRC
)
anti-cMET antibody-drug conjugate
Colorectal cancer
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - One Clinical Research
NCT06792695
Advanced
Phase 2
Recruiting
A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (
CANTOR
)
Bevacizumab
Fluorouracil
Irinotecan
Leucovorin
Volrustomig
anti-VEGF monoclonal antibody
antimetabolite
bispecific PD-L1/CTLA4 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,VEGF-targeting
therapeutic modality,bispecific antibody
topoisomerase inhibitor
Colorectal cancer
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06757634
Advanced
Phase 3
Recruiting
VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors With or Without Gedatolisib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer (
CELC-G-302
)
pan-PI3K/mTORC1/mTORC2 inhibitor
selective estrogen receptor degrader
Breast cancer
NSW
2076 - Wahroonga - Sydney Adventist Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
QLD
4215 - Southport - ICON Cancer Care
SA
5000 - South Australia - GenesisCare St Andrews Hospital
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06750094
Advanced
Phase 3
Recruiting
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (
OrigAMI-3
)
anti-EGFR monoclonal antibody
anti-VEGF monoclonal antibody
bispecific cMET/EGFR antibody
Colorectal adenocarcinoma
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Warringal Private Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06712355
Advanced
Phase 3
Recruiting
A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer (
BNT327-03
)
anti-PD-L1 monoclonal antibody
bispecific PD-L1/VEGFA antibody
platinum-based antineoplastic agent
topoisomerase inhibitor
Small-cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Cancer Care Wollongong
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4870 - Cairns - Cairns Base Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06492616
Curative
Phase 3
Recruiting
Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study (
ELEGANT
)
selective estrogen receptor degrader
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2060 - North Sydney - Mater Hospital
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2480 - Lismore - Lismore Base Hospital
VIC
3066 - Epping - Northern Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3630 - Shepparton - Goulburn Valley Health
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4215 - Southport - ICON Cancer Care
4812 - Hyde Park - Icon Cancer Centre Townsville
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT06417814
Advanced
Phase 3
Recruiting
A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment (
TROPION-Lung15
)
EGFR inhibitor,third generation
anti-Trop2 antibody-drug conjugate
Non-small cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2217 - Kogarah - St George Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06360354
Advanced
Phase 1
Recruiting
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion (
MTAPESTRY-103
)
PRMT5 inhibitor,MTA-co-operative
Pancreatic cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06345079
Advanced
Phase 2
Recruiting
A Randomised Study of Cessation of Somatostatin Analogues After Peptide Receptor Radionuclide Therapy in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours (
STOPNET
)
Octreotide
cancer therapy
endocrine therapy
endocrine therapy,somastatin axis-targeting
somatostatin analog
Neuroendocrine tumour
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06343402
Advanced
Phase 1
Recruiting
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study (
TBBO8520-101
)
KRAS G12C inhibitor
Colorectal adenocarcinoma
Non-small cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06333951
Advanced
Phase 1
Recruiting
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)
PRMT5 inhibitor,MTA-co-operative
Non-small cell lung cancer
Thoracic cancer
NSW
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06252649
Advanced
Phase 3
Recruiting
Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301) (
CodeBreaK-301
)
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
KRAS G12C inhibitor
anti-EGFR monoclonal antibody
anti-VEGF monoclonal antibody
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4350 - Toowoomba - Toowoomba Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
NCT05975073
Advanced
Phase 1 / Phase 2
cohorts full
A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors
MAT2A inhibitor
PRMT5 inhibitor,MTA-co-operative
Non-small cell lung cancer
Solid tumour
VIC
3168 - Clayton - Monash Medical Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT05785754
Advanced
Phase 1
Recruiting
A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors (
DCSZ11-101
)
anti-CD93 monoclonal antibody
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Scientia Clinical Research Ltd
2076 - Wahroonga - Sydney Adventist Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
4812 - Townsville - Townsville University Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT05694936
Advanced
Phase 2
Recruiting
A Phase II Trial to Determine the Efficacy of Combining the HDAC Inhibitor Sodium Valproate With EGFR Monoclonal Antibody (Panitumumab or Cetuximab) Maintenance in the First-line Treatment of Patients With RAS Wild Type Metastatic Colorectal Cancer (
VADER
Study).
HDAC inhibitor
anti-EGFR monoclonal antibody
Colorectal cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3199 - Frankston - Peninsula Health Frankston Hospital
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
NCT05215340
Advanced
Phase 3
Recruiting
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (
TROPION-Lung08
)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT05037760
Haem
Phase 2
Recruiting
A Phase 2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KER-050 as Monotherapy or in Combination With Ruxolitinib in Participants With Myelofibrosis (
KER050-MF-301
)
JAK1/JAK2 inhibitor
modified ActRIIA ligand trap protein
Myelofibrosis
NSW
2139 - Concord - Concord Repatriation General Hospital
2485 - Tweed Heads - The Tweed Hospital
VIC
3051 - North Melbourne - Melbourne Theranostic Innovation Centre
3066 - Epping - Northern Hospital
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT04164199
Advanced
Phase 3
Enrolling by invitation
An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies (
BGB-A317-290-LTE1
)
PARP inhibitor
anti-PD-1 monoclonal antibody
Cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT03486873
Advanced
Phase 3
Recruiting
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab (
3475-587
)
anti-PD-1 monoclonal antibody
Haematological malignancy
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre
2060 - North Sydney - Mater Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4120 - Greenslopes - Greenslopes Private Hospital
4215 - Southport - Gold Coast University Hospital
4215 - Southport - Tasman Oncology
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
ACTRN12624001230549
Curative
Phase 2 / Phase 3
Not yet recruiting
An assessment of cancer outcomes post cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases with the use of a personalised aproach to choice of intraperitoneal chemotherapy agent individualised to a patient's specific tumour sensitivity in-vitro.
Irinotecan
Mitomycin
Oxaliplatin
antineoplastic antibiotic
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
topoisomerase inhibitor
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6027 - Joondalup - Joondalup Health Campus
ACTRN12617001190392
Advanced
Phase 1 / Phase 2
Status unknown
An open label phase IB/II, non-randomised, dose-finding, safety and tolerability study of Panitumumab, Irinotecan, Trifluridine/Tipiracil in RAS wild-type patients with metastatic colorectal cancer (
PIT-Study
)
Tipiracil Hydrochloride
Trifluridine
anti-EGFR monoclonal antibody
antimetabolite
thymidine phosphorylase inhibitor
topoisomerase inhibitor
Colorectal cancer
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (25)
cohorts full (1)
Enrolling by invitation (1)
Not yet recruiting (1)
Status unknown (1)
Recruitment Country and State
SA (29)
VIC (25)
NSW (24)
QLD (16)
WA (14)
NZ (2)
TAS (1)
Phase
Phase 1 (6)
Phase 1 / Phase 2 (3)
Phase 2 (7)
Phase 2 / Phase 3 (3)
Phase 3 (10)
Trial Type
Advanced (25)
Curative (3)
Haem (1)
Cancer Therapy Class
PD-1/PD-L1
41%
PD-1
31%
EGFR
28%
VEGF
24%
KRAS
14%
PRMT5
14%
PD-L1
10%
VEGFR2
10%
Trop2
10%
MET
10%
KRAS G12C
10%
HDAC
7%
VEGFR1
7%
VEGFR3
7%
TIGIT
7%
ER
7%
oestrogen axis
7%
HRAS G12C
7%
NRAS G12C
7%
LAG3
7%
PARP
7%
PKC
3%
CTLA4
3%
CDK4
3%
CDK6
3%
PI3K
3%
PI3Kalpha
3%
mTOR
3%
mTORC1
3%
mTORC2
3%
VEGFA
3%
somastatin axis
3%
DPD
3%
orotate phosphoribosyltransferase
3%
MAT2A
3%
CD93
3%
gp100
3%
JAK1
3%
JAK2
3%
ERBB2
3%
HPK1
3%
KIT
3%
OX40
3%
PDGFR
3%
RET
3%
TIM3
3%
VEGFR
3%
Facility
5011 - Woodville South - The Queen Elizabeth Hospital (29)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (11)
3168 - Clayton - Monash Medical Centre (8)
2050 - Camperdown - Chris O'Brien Lifehouse (7)
3000 - Melbourne - Peter MacCallum Cancer Centre (7)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (6)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (6)
5042 - Bedford Park - Flinders Medical Centre (6)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (6)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (6)
2170 - Liverpool - Liverpool Hospital (5)
3021 - St Albans - Western Health - Sunshine Hospital (5)
4102 - Woolloongabba - Princess Alexandra Hospital (5)
2109 - North Ryde - Macquarie University Hospital (4)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (4)
3199 - Frankston - Peninsula Health Frankston Hospital (4)
6009 - Nedlands - Linear Clinical Research (3)
3066 - Epping - Northern Hospital (3)
6150 - Murdoch - Fiona Stanley Hospital (3)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (3)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (3)
2217 - Kogarah - St George Hospital (3)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (3)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (3)
2031 - Randwick - Scientia Clinical Research Ltd (2)
4120 - Greenslopes - Greenslopes Private Hospital (2)
3004 - Melbourne, Southbank - Alfred Health (2)
4215 - Southport - Tasman Oncology (2)
2065 - St Leonards - GenesisCare North Shore Private Hospital (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
2500 - Wollongong - Wollongong Hospital (2)
2076 - Wahroonga - Sydney Adventist Hospital (2)
4215 - Southport - ICON Cancer Care (2)
2139 - Concord - Concord Repatriation General Hospital (2)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
2060 - North Sydney - Mater Hospital (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
3065 - Fitzroy - St Vincent's Hospital Melbourne (2)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (2)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
3011 - Footscray - Footscray Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
NA
6150 - Murdoch - St John of God Murdoch Hospital (1)
6009 - Nedlands - One Clinical Research (1)
3002 - East Melbourne - Epworth Freemasons (1)
5000 - South Australia - GenesisCare St Andrews Hospital (1)
3084 - Heidelberg - Warringal Private Hospital (1)
2500 - Wollongong - Cancer Care Wollongong (1)
4870 - Cairns - Cairns Base Hospital (1)
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital (1)
2480 - Lismore - Lismore Base Hospital (1)
3630 - Shepparton - Goulburn Valley Health (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
4350 - Toowoomba - Toowoomba Hospital (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
4812 - Townsville - Townsville University Hospital (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
2485 - Tweed Heads - The Tweed Hospital (1)
3051 - North Melbourne - Melbourne Theranostic Innovation Centre (1)
2031 - Randwick - Prince of Wales Hospital (1)
2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre (1)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (1)
4215 - Southport - Gold Coast University Hospital (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
6027 - Joondalup - Joondalup Health Campus (1)
Cancer Type
Cancer
Solid tumour
Gastrointestinal cancer
Colorectal cancer
Lower gastrointestinal cancer
Lung cancer
Respiratory tract cancer
Thoracic cancer
Non-small cell lung cancer
Melanoma
Pancreatic cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
Breast cancer
Colorectal adenocarcinoma
Haematological malignancy
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Uveal melanoma
Non-squamous non-small-cell lung cancer
Carcinoma
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Neuroendocrine tumour
Myelofibrosis
Myeloproliferative neoplasm
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy